Law and regulation
Binding requirements are identified by jurisdiction and cited to the controlling text when publicly available. We do not present a guidance document or industry practice as if it were a regulation.
Evidence policy
YB Inspection publishes technical content for pharmaceutical visual-inspection teams. Our goal is to make each claim traceable, label the authority of each source correctly, and separate general information from site-specific decisions.
Last materially reviewed: September 26, 2026
Our editorial commitment
A technically accurate sentence can still mislead if the source is described incorrectly. We distinguish binding requirements, compendial standards, final or draft guidance, industry consensus, scientific literature, and site-defined choices. Where a numerical value or acceptance criterion is not universal, we say so.
Binding requirements are identified by jurisdiction and cited to the controlling text when publicly available. We do not present a guidance document or industry practice as if it were a regulation.
USP, Ph. Eur., JP, and other pharmacopeial material is described with its chapter or monograph status and applicable scope. Informational chapters are not described as universally mandatory requirements.
Final and draft guidance are labelled separately. Draft guidance is described as nonbinding agency thinking and not as an implemented rule or automatic authorization.
PDA, ISPE, ECA, BioPhorum, and peer-reviewed literature may support technical interpretation, but they are identified as industry or scientific sources rather than law.
YB articles and downloadable tools are educational frameworks. They do not establish a product-specific validation conclusion, batch disposition, acceptance criterion, legal interpretation, or regulatory strategy. Each organization remains responsible for approving its own procedures, protocols, risk assessments, and market-specific requirements.